Answers are grounded in this paper and cite their sources.
Excitement around and investment in oncology drug development are at unprecedented levels. To maximize the health impact and productivity of this research and development investment, quantitative modeling should impact key decisions in early clinical oncology including Go/No-Go decisions based on early clinical data, and dose selection for late stage studies. See related article by Bottino et al., p. 6633
No takes yet. Share an insight, caveat, or question.
Mayawala et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: